Apollo Hospitals Enterprise Ltd Q1 FY2026 Concall Summary

Key Takeaways

• ARPP replaces ARPOB, up 9%: The new metric isolates pricing and case mix from length-of-stay effects, with roughly half the growth from tariffs and half from a shift toward complex Congo specialties.
• 24/7 digital business on track for breakeven: GMV was restated to count only new customers, yet management reaffirmed the FY26 breakeven target and guided to 25–30% full-year GMV growth on the new definition.
• Pharmacy demerger unlocks value: Apollo HealthCo (retail + online) will be listed separately by Q4 FY27, merged with Keimed, targeting a combined ₹25,000 crore revenue run-rate at 7% EBITDA margin.
• Hospital margins to dip then expand: New hospital losses of up to ₹150 crore over two years will compress margins by ~100 bps before the planned climb to 25%+ EBITDA, with occupancy improvement expected from Q2 onward.
• What to watch next quarter: Whether hospital volume growth accelerates from 11% toward the guided 13–14%, the pace of 24/7 GMV build toward the ₹800–900 crore breakeven threshold, and any stabilization in Bangladesh international patient flows.

Hospital Performance & the ARPP Reset

• Metric change, not business change: Management discontinued ARPOB because external stakeholders were misrepresenting it as pure price inflation; ARPP (₹172,282, +9% YoY) better isolates realization by removing length-of-stay and occupancy noise.
• Growth composition: Tariff increases contributed ~4–5% of the 9% ARPP growth, with the remainder from case mix, especially Congo specialties where gastro sciences revenue rose 16% and orthopedics 17% YoY. Volume growth was driven almost entirely by these same specialties.
• Payer mix shift: Insurance volume grew fastest at 7.8%, cash volume at ~5%, supporting the case-mix improvement as insured patients tend toward higher-complexity procedures.
• ALOS down 6% intentionally: Length of stay fell to 3.06 days (from 3.23 in Q4) due to robotic surgeries and minimally invasive procedures, freeing capacity equivalent to 550–600 beds for supply-side growth in high-complexity metro care.
• Volume headwinds: Headline volume growth of 3% was dragged by IPS (Bangladesh); insurance and walk-in volumes grew 5% and 7% respectively. Bangladesh volumes have recovered somewhat from the Nov–Dec trough but remain below prior-year levels.
• International patient diversification: Iraq has emerged as a new source market with healthy margins, feeding Hyderabad and Chennai; management targets international patients at 7% of hospital revenue by year-end and 10% next year, up from the current 5%.

Madhu Sasidhar: "a lot of the occupancy number that you see has been intentional. It is a 6% reduction in length of stay, which is almost like adding 550, 600 beds, right. What this gives us is the extra capacity in our chassis to focus on supply side."

24/7 Digital Business & GMV Restatement

• GMV redefined to new customers only: Hospital IPOP and consult lines now count only business from new customers brought to the Apollo Group; existing customers generate a servicing charge. Pharmacy and diagnostics GMV booking is unchanged. Restated numbers show 8% sequential and 23% YoY growth.
• Revenue-to-GMV ratio unchanged: Despite the GMV restatement (which lowered the denominator), management kept the full-year guidance at ~45–46%, implying the revenue story is intact even as GMV optics shift.
• Breakeven math: The business needs GMV of ₹800–900 crore and revenue of ₹90–100 crore to break even; full-year GMV is guided to ₹3,000–3,200 crore, implying 25–30% growth on the new definition.
• Cost reduction levers working: Improved unit economics across customer acquisition charges, discounts, lifecycle cost, and delivery cost; pharmacy CM1 marginal contribution is near break-even; marketing spend has been reduced.
• Pharmacy margin jump: 340 bps QoQ improvement driven by renegotiated service-provider rates, better pharmacy unit economics, higher insurance commission (₹5 crore vs ₹1–1.5 crore in Q4), and monetization gains.
• Quick-commerce competition: Management sees aggressive new entrants expanding the digital pharmacy market and generating trials, but will not compete on customer-acquisition cost; the bet is on Apollo's trust, supply chain, and quality winning long-term.
• Growth expectations tempered: Management explicitly asked investors not to expect "astronomical growth," guiding to 20–25% YoY as the digital business continues investing in assets like patient health records and Ask Apollo AI.

Madhivanan B: "Incremental players coming in with aggressive strategies, my mind will expand the digital market and give greater amount of trials. And here, I think Apollo, given its very strong trust, very strong supply chain capabilities, and the ability to offer always good quality, trusted medicines should hold on in the long run. We are not going to be in this war for acquiring customers at any cost but build a much more stronger sustainable business under the direction of our Board."

Pharmacy Demerger & Keimed Integration

• Structure and timeline: Apollo HealthCo (retail pharmacies + online) will be demerged and listed separately; the NCLT process to merge Keimed into this entity will complete by Q4 FY27, with all steps concluding within 18–21 months. Hospital-based pharmacies remain with the hospitals business.
• Combined scale ambition: The merged entity targets a run-rate of ₹25,000 crore revenue with 7% EBITDA margin by Q4 FY27, with Keimed margins already improving 40 bps from 3.1% to 3.5% driven by scale and operating leverage.
• Synergy levers: Integration benefits span technology, people, and cost; the combined network can set up more economical dark stores (currently 22) for expansion beyond the top 6 cities into the next 10 and the rest of India; private-label generics (currently 14.6%) can be driven across the Apollo chain, Apollo Digital, and Keimed franchises.
• Offline pharmacy steady: Margins stable at 7.7% due to the fixed cost-plus model to the front end; private-label share has been flat for two quarters due to product repositioning, with a new head appointed to drive expansion. Store additions planned at ~600 annually, with revenue growth of 17–18% focused on Central and South regions.

Hospital Margin Path & New Bed Absorption

• Near-term compression, then expansion: Management expects a marginal dip of ~100 bps from current hospital margins as new facilities ramp, then expansion to 25% or 25%+ EBITDA. The total EBITDA impact from new hospitals is capped at ~₹150 crore over a two-year period, a manageable number against a base of ₹2,800 crore.
• New hospital economics: Most new facilities are expected to break even within 12 months and reach double-digit margins shortly after, limiting the duration of the drag.
• Occupancy recovery expected from Q2: The intentional ALOS reduction created headroom; occupancy improvement is expected to begin in Q2 and continue through Q3 and Q4, driven by secondary care focus, payer mix alignment, corporate and PSU tie-ups, and international patient uplift from new markets.
• Organic growth target: Existing assets are expected to deliver ~13–14% growth, with an additional ~10% from new beds over the next 2–3 years. Q1 delivered only 11%, and management did not quantify the specific volume-versus-price contribution needed to close the gap.

A. Krishnan: "on that scale of EBITDA of Rs. 2,800 crore, having Rs. 100 crore, Rs. 150 crore EBITDA would not be a big number."

New Ventures: Insurance, App Monetization & Diagnostics

• Digital insurance launched: The business generated ₹5 crore in Q1 revenue against a ₹7 crore target, with partners including Niva Bupa, Care, and Star Health across health and life products. Management is confident it will not detract from breakeven objectives by year-end, though investment in people and technology will continue.
• Corporate partnerships scaling: An SBI partnership has started, and a "one Apollo" approach is being taken to larger corporates, bundling hospital, pharmacy, and insurance offerings.
• App monetization gaining traction: The Apollo app is working with weight-loss drugs, mega pharmacy brands, and strong FMCG brands; management described the story as "picking up."
• Diagnostics margin one-off: Q1 EBITDA was impacted by validation costs from the new Central Reference Laboratory in Chennai (opened 30 April, 45,000 sq ft, fully automated DigiLab); normalized margin is 10.3%.

Guidance & Commitments

Key Metrics